A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases

Last updated: January 28, 2025
Sponsor: Acusurgical
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hemorrhage

Treatment

vitreoretinal surgery

Clinical Study ID

NCT06294613
CIV-23-07-043672
  • Ages 18-85
  • All Genders

Study Summary

Prospective, interventional, open-label, non-controlled, monocentric study in Belgium of Luca, of up to 15 evaluable subjects, undergoing vitreoretinal surgery to treat intravitreal hemorrhage and macular pucker.

Only one eye per subject can be enrolled.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Given written Informed Consent by subject,

  • Males or females aged 18 - 85 years, pseudophakic or aphakic,

  • Willing and able to comply with the schedule for follow-up visits,

  • Requiring vitrectomy under general anesthesia (conditions include vitreoushemorrhage treatment (with potential clinical conditions including diabeticretinopathy, vascular occlusion, adverse effect of anticoagulant therapy), macularpucker),

  • BCDVA <7/10,

  • Deemed fit for robotic surgery per surgeons' assessment, including ability toundergone general anesthesia,

  • Beneficiary of health insurance.

Exclusion

Exclusion Criteria:

  • Uncontrolled systemic disease that could increase the operative risk or confound theoutcome (autoimmune disease, uncontrolled hypertension, lung and heart diseaseimpairing respiratory function, or any other medical condition as deemed by theClinical Investigator),

  • BMI (kg/m²) > 30,

  • Axial length <22 or >26 mm per ocular biometry, inclusive,

  • Presence of clinically significant ocular inflammation or infection within 30 daysof Preop Visit, such as CME, uveitis, etc.,

  • Ocular condition, that in the opinion of the Clinical Investigator, may predisposefor future complications or confound visual acuity results, including profoundamblyopia (<1/10) or strabismus,

  • Ocular condition presenting associated pathology likely to require additionalsurgical manipulation, such as known need for membrane peeling, or retinalneovacular formation to be cut,

  • Already vitrectomized on the study eye,

  • Presenting retinal detachment or retinal tear,

  • History of ocular traumatism; post-traumatic vitreous hemorrhage,

  • Corneal scar preventing clear visualization of fundus,

  • Any associated ocular pathology or ocular degenerative disorder that is uncontrolledsuch as glaucoma with clinical visual defect or IOP not controlled by medicaltreatment, uveitis, optic nerve damage,

  • Subjects without light perception,

  • Subject participating in other clinical studies,

  • Subject being dependent on the Sponsor or Clinical Investigator,

  • Pregnant or lactating women, based on self-declaration.

Study Design

Total Participants: 15
Treatment Group(s): 1
Primary Treatment: vitreoretinal surgery
Phase:
Study Start date:
February 08, 2024
Estimated Completion Date:
July 31, 2026

Connect with a study center

  • UZ Gent

    Gent, East Flanders 9000
    Belgium

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.